Chronic fluvoxamine treatment changes 5-HT(2A/2C) receptor-mediated behavior in olfactory bulbectomized mice.
Akira Oba, Osamu Nakagawasai, Hiroshi Onogi, Wataru Nemoto, Fukie Yaoita, Yuichiro Arai, Koichi Tan-No, Takeshi Tadano
Index: Life Sci. 92(2) , 119-24, (2013)
Full Text: HTML
Abstract
Olfactory bulbectomy (OBX) in rodents represents a valuable experimental model of depression. This study was designed to shed further light on the impact of putative serotonergic neuronal degeneration in OBX mice and to assess the effect of a widely used antidepressant on serotonergic related behavioral changes induced by OBX.Adult male ddY mice were subject to bilateral OBX or sham surgery. The serotonin (5-HT)(2A/2C) receptor agonist 2,5-dimethoxy-4-iodoamphetamine (DOI) enhanced a head-twitch response (HTR) in OBX mice. Effects of 5-HT(2A), 5-HT(2C) antagonists and fluvoxamine were observed in OBX mice following DOI administration.The HTR elicited by the administration of DOI (0.5 mg/kg and 1 mg/kg, i.p.) was increased about twofold in OBX mice when compared with controls on the 14th day after the surgery. The injection of ketanserin (0.025 mg/kg, i.p.), a 5-HT(2A) receptor antagonist, inhibited the enhancement of the DOI-induced HTR after OBX. Likewise, the administration of SB 242084 (1 mg/kg, s.c.), a 5-HT(2C) receptor antagonist, also inhibited the DOI-induced HTR in OBX mice. Chronic but not acute treatment with the antidepressant fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), suppressed the enhancement of DOI-induced HTR after OBX.These findings indicate that OBX, and the subsequent degeneration of neurons projecting from the olfactory bulb, caused a supersensitivity of 5-HT(2A/2C) receptors which may be involved in symptoms of depression.Copyright © 2012 Elsevier Inc. All rights reserved.
Related Compounds
Related Articles:
2014-01-01
[J. Pharm. Pharm. Sci. 17(3) , 427-38, (2014)]
2013-02-01
[J. Clin. Psychopharmacol. 33(1) , 131-2, (2013)]
2015-10-01
[Behav. Pharmacol. 26 , 681-90, (2015)]
2014-08-01
[J. Pharmacol. Exp. Ther. 350(2) , 403-11, (2014)]
2014-04-01
[FASEB J. 28(4) , 1735-44, (2014)]